Seattle brothers expand billion-dollar company’s focus to include COVID
Adaptive Biotechnologies, a Seattle-based biotech company founded to search for cures to cancer, is now expanding its mission to develop solutions to fight COVID-19 by analyzing immune responses to different diseases through its blood testing technology.
“Your immune system knows about every disease you have…If we could just ask the immune system what it knows, we would be able to diagnose every disease,” said Harlan Robins, chief scientific officer at Adaptive.
The company was created by two brothers out of the Fred Hutchinson Cancer Research Center in 2009. Today Adaptive Biotechnologies has a staff of 800 employees is valued at approximately $5.5 billion.